Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in resected high risk colon cancer patients. - The PIPAC-OPC3 CC trial,

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519189-31-00

Acronym

PIPACOPC3CC

Enrollment

Registered

2024-12-03

Start date

2024-12-04

Completion date

Unknown

Last updated

2024-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon cancer

Brief summary

The proportion of patients with peritoneal recurrence on contrast enhanced CT of the thorax and abdomen 36 months after resection of high-risk colon cancer

Detailed description

Treatment related toxicity and complication rate, Completion rate of two adjuvant PIPAC treatments, 1- and 2-year peritoneal recurrence free survival, based on CT of the thorax and abdomen, 1-, 2- and 3-year recurrence free survival, based on CT of the thorax and abdomen, 1-, 3- and 5-year overall survival rate, The number of conversions from positive to negative peritoneal lavage cytology after one PIPAC procedure

Interventions

DRUGOXALIPLATIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The proportion of patients with peritoneal recurrence on contrast enhanced CT of the thorax and abdomen 36 months after resection of high-risk colon cancer	—

Secondary

Measure	Time frame
Treatment related toxicity and complication rate, Completion rate of two adjuvant PIPAC treatments, 1- and 2-year peritoneal recurrence free survival, based on CT of the thorax and abdomen, 1-, 2- and 3-year recurrence free survival, based on CT of the thorax and abdomen, 1-, 3- and 5-year overall survival rate, The number of conversions from positive to negative peritoneal lavage cytology after one PIPAC procedure	—

Measure

Time frame

—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026